On December 1, 2017 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, reported an upcoming presentation at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition Dec. 9, 2017, in Atlanta (Press release, Curis, DEC 1, 2017, View Source [SID1234522330]). This presentation will provide an analysis of results from the Phase 2 trial of CUDC-907.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date/Time: Saturday, Dec. 9, 5:30 p.m. — 7:30 p.m. EST
Abstract Number: 1555
Presentation Title: Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907
Location: Building A, Level 1, Hall A2, Georgia World Congress Center, Atlanta
Additional information on the poster presentation can be accessed at View Source